Ciecielski Katrin Jana, Berninger Alexandra, Algül Hana
Comprehensive Cancer Center Munich (CCCM), Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Visc Med. 2020 Oct;36(5):373-380. doi: 10.1159/000509232. Epub 2020 Oct 6.
Pancreatic ductal adenocarcinoma (PDAC), with a mortality rate of 94% and a 5-year-survival rate of only 8%, is one of the deadliest cancer entities worldwide, and early diagnostic methods as well as effective therapies are urgently needed.
This review summarizes current clinical procedure and recent developments of oncological therapy in the palliative setting of metastatic PDAC. It further gives examples of successful, as well as failed, targeted therapy approaches and finally discusses promising ongoing research into the decade-old question of the "undruggability" of KRAS.
Bench-driven concepts change the clinical landscape from "one size fits all" towards precision medicine. With growing insight into the molecular mechanisms of pancreatic cancer the era of targeted therapy in PDAC is gaining a new momentum.
胰腺导管腺癌（PDAC）的死亡率为94%，5年生存率仅为8%，是全球最致命的癌症类型之一，迫切需要早期诊断方法和有效的治疗方法。
本综述总结了转移性PDAC姑息治疗中的当前临床程序和肿瘤治疗的最新进展。它还给出了成功和失败的靶向治疗方法的例子，最后讨论了针对KRAS“不可成药”这一由来已久问题的正在进行的有前景的研究。
基于实验室研究的概念正在将临床格局从“一刀切”转变为精准医学。随着对胰腺癌分子机制的深入了解，PDAC的靶向治疗时代正获得新的动力。
